HomeCompareMXDHF vs BTI

MXDHF vs BTI: Dividend Comparison 2026

MXDHF yields 800.00% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MXDHF wins by $2773896.43M in total portfolio value
10 years
MXDHF
MXDHF
● Live price
800.00%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2773896.46M
Annual income
$2,226,430,694,490.38
Full MXDHF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — MXDHF vs BTI

📍 MXDHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMXDHFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MXDHF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MXDHF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MXDHF
Annual income on $10K today (after 15% tax)
$68,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,892,466,090,316.82/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, MXDHF beats the other by $1,892,466,087,948.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MXDHF + BTI for your $10,000?

MXDHF: 50%BTI: 50%
100% BTI50/50100% MXDHF
Portfolio after 10yr
$1386948.25M
Annual income
$1,113,215,348,638.51/yr
Blended yield
80.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

MXDHF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-3.4
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MXDHF buys
0
BTI buys
0
No recent congressional trades found for MXDHF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMXDHFBTI
Forward yield800.00%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$2773896.46M$37.7K
Annual income after 10y$2,226,430,694,490.38$2,786.64
Total dividends collected$2730603.49M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: MXDHF vs BTI ($10,000, DRIP)

YearMXDHF PortfolioMXDHF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$90,700$80,000.00$11,299$598.92+$79.4KMXDHF
2$775,180$678,130.84$12,794$703.91+$762.4KMXDHF
3$6,246,019$5,416,576.76$14,518$829.07+$6.23MMXDHF
4$47,472,138$40,788,897.61$16,513$978.64+$47.46MMXDHF
5$340,525,323$289,730,135.14$18,827$1,157.84+$340.51MMXDHF
6$2,306,680,888$1,942,318,792.24$21,518$1,373.12+$2306.66MMXDHF
7$14,764,459,529$12,296,310,979.28$24,657$1,632.46+$14764.43MMXDHF
8$89,354,478,583$73,556,506,887.09$28,329$1,945.74+$89354.45MMXDHF
9$511,650,252,638$416,040,960,553.41$32,637$2,325.33+$511650.22MMXDHF
10$2,773,896,464,813$2,226,430,694,490.38$37,708$2,786.64+$2773896.43MMXDHF

MXDHF vs BTI: Complete Analysis 2026

MXDHFStock

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Full MXDHF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this MXDHF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MXDHF vs SCHDMXDHF vs JEPIMXDHF vs OMXDHF vs KOMXDHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.